Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy

Lomas, M, Liauw, W, Packham, D, Williams, K, Kelleher, A, Zaunders, J and Ward, R (2004) Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy. Annals of Oncology, 15 2: 324-329. doi:10.1093/annonc/mdh053

Author Lomas, M
Liauw, W
Packham, D
Williams, K
Kelleher, A
Zaunders, J
Ward, R
Title Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy
Journal name Annals of Oncology   Check publisher's open access policy
ISSN 0923-7534
Publication date 2004
Sub-type Article (original research)
DOI 10.1093/annonc/mdh053
Volume 15
Issue 2
Start page 324
End page 329
Total pages 6
Language eng
Subject 2730 Oncology
1306 Cancer Research
Abstract Background: The purpose of this study was to induce immunity to p53 by using an idiotypic vaccine, composed of a pool of eight peptides derived from the complimentarity determining regions (CDRs) of human anti-p53 antibodies. Patients and methods: Subjects with advanced malignancy received up to four, monthly intradermal injections of pooled peptides (500 μg of each) admixed with granulocyte-macrophage colony-stimulating factor (GM-CSF; 100 μg). In addition, two sheep and two rabbits were also vaccinated with the pooled peptides. Results: Fourteen subjects were enrolled into the study and six of these completed the vaccination schedule. The vaccine was well tolerated by all subjects and no major adverse events were attributable to the vaccine. All subjects mounted in vivo delayed type hypersensitivity (DTH) responses to two or more of the individual vaccine peptides. Vaccine-induced antibodies specific for peptides 2,5 or 8 were detected in four of six subjects, and two of these had vaccine-specific, cell-mediated responses. Increasing titers of p53-specific antibodies were found in one patient. No T-cell response to p53 was observed in any of the subjects. All animals developed humoral immunity to the peptides and one of the sheep developed rising serum titers of anti-p53 antibodies. Conclusions: Vaccination with human antibody CDR regions represents a novel method for inducing human antibodies, which may in turn serve as immunological mimics of p53.
Keyword Cancer
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collection: Scopus Import
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 13 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 11 Feb 2015, 11:30:44 EST by Ms Kate Rowe